Research across Cancer
Related studies from across the Cancer family.
Case report details multimodal treatment for aggressive thyroid carcinoma
First new treatment combination in six months stabilizes advanced thyroid cancer
A 61-year-old man with papillary thyroid carcinoma achieved disease stabilization after thyroidectomy, radiotherapy, and targeted therapy. T…
A 61-year-old man with advanced thyroid cancer saw his disease stop growing after a specific mix of treatments within six months of his diag…
Case review of epithelial-type Wilms tumor in a 23-year-old female with clear surgical margins
A rare kidney tumor in a young adult was removed with clear margins and no spread
This case review describes a 23-year-old female who underwent right radical nephrectomy for a rare epithelial-type Wilms tumor. Histopatholo…
A 23-year-old woman had a rare kidney tumor removed. The surgery showed clear edges and no spread. This case highlights the need for awarene…
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
At-a-Glance
This review of a case report describes two patients with unresectable intraductal papillary mucinous neoplasms of the bile duct treated with…
A new three-drug combination shrank a rare bile duct tumor in one patient and stopped another from growing, offering hope for a cancer with …
Kidney-directed SBRT shows modest renal function decline in inoperable patients
Small study shows kidney function drops after radiation for hard-to-treat tumors
This prospective phase 2 single-arm trial evaluated kidney-directed SBRT in 30 patients with primary or metastatic renal tumors who were med…
Radiation to treat kidney tumors may lower kidney function over two years, even when surgery is not an option.
Nephrometry Scores Show Limited Discrimination for Adverse Outcomes After RAPN in Larger Renal Tumors
Tumor complexity scores predict longer surgery time but not major complications in kidney cancer removal
This retrospective cohort study of 109 patients with pT1b–pT2a renal tumors found that PADUA and RENAL nephrometry scores had limited discri…
Scores measuring kidney tumor complexity predicted longer surgery time but failed to predict major complications in 109 patients.
Case series describes four clear cell variant papillary thyroid carcinoma cases with NCOA4-RET fusions
Rare Thyroid Cancer Has Unique Genetic Signature
This case series with literature review describes four pathologically confirmed cases of clear cell variant of papillary thyroid carcinoma d…
A rare thyroid cancer type may have a specific genetic cause that doctors can now look for.
Radical nephrectomy performed for renal inflammatory myofibroblastic tumor in an elderly female
Rare Kidney Tumor Treated Successfully With Surgery Alone
This is a case report of an elderly female patient who underwent radical right nephrectomy for a renal inflammatory myofibroblastic tumor.
A rare kidney tumor was removed with surgery, and no recurrence was seen at 6 months. But this is just one case.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Autopsy study finds 55% thyroid nodular disease prevalence in Mexico City hospital patients
Autopsy study finds high thyroid nodule rates in Mexico City, no link to salt iodination
A retrospective cohort study of 487 autopsies from a third-level hospital in Mexico City found a thyroid nodular disease prevalence of 55% a…
Autopsies in Mexico City reveal thyroid nodules are very common, yet changing salt iodination rules did not increase their rates.
Simlukafusp alfa plus atezolizumab with or without bevacizumab shows antitumor activity in metastatic renal cell carcinoma
Does adding bevacizumab nearly triple the time before kidney cancer grows back?
A phase Ib randomized open-label study in 66 patients with metastatic renal cell carcinoma found objective response rates of 25% with simluk…
Adding bevacizumab nearly tripled the time before kidney cancer grew back compared to a two-drug mix in this early study.